Skip to main content
Top
Published in: Diabetologia 10/2013

01-10-2013 | Article

Clinical characteristics influence screening intervals for diabetic retinopathy

Authors: Massimo Porta, Mauro Maurino, Sara Severini, Elena Lamarmora, Marina Trento, Elena Sitia, Eleonora Coppo, Alessandro Raviolo, Stefania Carbonari, Marcello Montanaro, Lorenza Palanza, Paola Dalmasso, Franco Cavallo

Published in: Diabetologia | Issue 10/2013

Login to get access

Abstract

Aims/hypothesis

Most guidelines recommend annual screening for diabetic retinopathy (DR) but limited resources and the slow progression of DR suggest that longer recall intervals should be considered if patients have no detectable lesions. This study aimed to identify the cumulative incidence and time of development of referable DR in patients with no DR at baseline, classified by clinical characteristics.

Methods

Analysis was performed of data collected prospectively over 20 years in a screening clinic based in a teaching hospital according to a consensus protocol. The cumulative incidence, time of development and relative risk of developing referable retinopathy over 6 years following a negative screening for DR were calculated in 4,320 patients, stratified according to age at onset of diabetes (<30 or ≥30 years), being on insulin treatment at the time of screening and known duration of diabetes (<10 or ≥10 years).

Results

The 6 year cumulative incidence of referable retinopathy was 10.5% (95% CI 9.4, 11.8). Retinopathy progressed within 3 years to referable severity in 6.9% (95% CI 4.3, 11.0) of patients with age at onset ≥30 years, who were on insulin treatment and had a known disease duration of 10 years or longer. The other patients, especially those with age at onset <30 years, on insulin and <10 years duration, progressed more slowly.

Conclusions/interpretation

Screening can be repeated safely at 2 year intervals in any patient without retinopathy. Longer intervals may be practicable, provided all efforts are made to ensure adherence to standards in procedures and to trace and recall non-attenders.
Literature
1.
2.
go back to reference American Diabetes Association (2012) Standards of medical care in diabetes–2012. Diabetes Care 35(suppl 1):S11–S63 American Diabetes Association (2012) Standards of medical care in diabetes–2012. Diabetes Care 35(suppl 1):S11–S63
4.
go back to reference Retinopathy Working Party (1991) A protocol for screening for diabetic retinopathy in Europe. Diabet Med 8:263–267CrossRef Retinopathy Working Party (1991) A protocol for screening for diabetic retinopathy in Europe. Diabet Med 8:263–267CrossRef
5.
go back to reference Kohner EM, Porta M (1992) Screening for diabetic retinopathy in Europe: a field guide-book. World Health Organization, Copenhagen Kohner EM, Porta M (1992) Screening for diabetic retinopathy in Europe: a field guide-book. World Health Organization, Copenhagen
6.
go back to reference Younis N, Broadbent DM, Vora JP, Harding SP (2003) Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 361:195–200PubMedCrossRef Younis N, Broadbent DM, Vora JP, Harding SP (2003) Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 361:195–200PubMedCrossRef
7.
go back to reference Vijian S, Hofer TP, Hayward RA (2000) Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 283:889–896CrossRef Vijian S, Hofer TP, Hayward RA (2000) Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 283:889–896CrossRef
8.
go back to reference Maguire A, Chan A, Cusumano J et al (2005) The case for biennial retinopathy screening in children and adolescents. Diabetes Care 28:509–513PubMedCrossRef Maguire A, Chan A, Cusumano J et al (2005) The case for biennial retinopathy screening in children and adolescents. Diabetes Care 28:509–513PubMedCrossRef
9.
go back to reference Agardh E, Tarabat-Khani P (2011) Adopting 3-year screening intervals for sight-threatening retinal vascular lesions in type 2 diabetic subjects without retinopathy. Diabetes Care 34:1318–1319PubMedCrossRef Agardh E, Tarabat-Khani P (2011) Adopting 3-year screening intervals for sight-threatening retinal vascular lesions in type 2 diabetic subjects without retinopathy. Diabetes Care 34:1318–1319PubMedCrossRef
10.
go back to reference Aspelund T, Thornórisdóttir O, Olafsdottir E et al (2011) Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. Diabetologia 54:2525–2532PubMedCrossRef Aspelund T, Thornórisdóttir O, Olafsdottir E et al (2011) Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. Diabetologia 54:2525–2532PubMedCrossRef
11.
go back to reference Chalk D, Pitt M, Vaidya B, Stein K (2012) Can the retinal screening interval be safely increased to 2 years for type 2 diabetic patients without retinopathy? Diabetes Care 35:1663–1668PubMedCrossRef Chalk D, Pitt M, Vaidya B, Stein K (2012) Can the retinal screening interval be safely increased to 2 years for type 2 diabetic patients without retinopathy? Diabetes Care 35:1663–1668PubMedCrossRef
12.
go back to reference Thomas RL, Dunstan F, Luzio SD et al (2012) Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis. BMJ 344:e874PubMedCrossRef Thomas RL, Dunstan F, Luzio SD et al (2012) Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis. BMJ 344:e874PubMedCrossRef
13.
go back to reference Gibbins RL, Owens DR, Allen JC, Eastman L (1998) Practical application of the European Field Guide in screening retinopathy by using ophthalmoscopy and 35 mm retinal slides. Diabetologia 41:59–64PubMedCrossRef Gibbins RL, Owens DR, Allen JC, Eastman L (1998) Practical application of the European Field Guide in screening retinopathy by using ophthalmoscopy and 35 mm retinal slides. Diabetologia 41:59–64PubMedCrossRef
14.
go back to reference Agardh E, Agardh CD, Hansson-Lundblad C (1993) The five-year incidence of blindness after introducing a screening programme for early detection of treatable diabetic retinopathy. Diabet Med 10:555–559PubMedCrossRef Agardh E, Agardh CD, Hansson-Lundblad C (1993) The five-year incidence of blindness after introducing a screening programme for early detection of treatable diabetic retinopathy. Diabet Med 10:555–559PubMedCrossRef
15.
go back to reference Backlund LB, Algvere PV, Rosenqvist U (1994) New blindness in diabetes reduced by more than one-third in Stockholm County. Diabet Med 14:732–740CrossRef Backlund LB, Algvere PV, Rosenqvist U (1994) New blindness in diabetes reduced by more than one-third in Stockholm County. Diabet Med 14:732–740CrossRef
16.
go back to reference Sivieri R, Rovera A, Porta M (1995) SEE (Save Eyes in Europe): the London protocol in software. Giornale Italiano di Diabetologia 15(Suppl):37–38 Sivieri R, Rovera A, Porta M (1995) SEE (Save Eyes in Europe): the London protocol in software. Giornale Italiano di Diabetologia 15(Suppl):37–38
17.
go back to reference Early Treatment Diabetic Retinopathy Study Research Group (1991) Grading diabetic retinopathy from stereoscopic colour fundus photographs—an extension of the modified Airlie House classification. ETDRS report no 10. Ophthalmology 98:786–806 Early Treatment Diabetic Retinopathy Study Research Group (1991) Grading diabetic retinopathy from stereoscopic colour fundus photographs—an extension of the modified Airlie House classification. ETDRS report no 10. Ophthalmology 98:786–806
18.
go back to reference Stratton I, Kohner EM, Aldington SJ et al (2001) UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 44:156–163PubMedCrossRef Stratton I, Kohner EM, Aldington SJ et al (2001) UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 44:156–163PubMedCrossRef
19.
go back to reference Aldington SJ, Kohner EM, Meuer S, Klein R, Sjølie AK (1995) Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia 38:437–444PubMedCrossRef Aldington SJ, Kohner EM, Meuer S, Klein R, Sjølie AK (1995) Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia 38:437–444PubMedCrossRef
20.
go back to reference Stefansson E, Bek T, Porta M, Larsen N, Kristinsson JK, Agardh E (2000) Screening and prevention of diabetic blindness. Acta Ophthalmol Scand 78:374–385PubMedCrossRef Stefansson E, Bek T, Porta M, Larsen N, Kristinsson JK, Agardh E (2000) Screening and prevention of diabetic blindness. Acta Ophthalmol Scand 78:374–385PubMedCrossRef
21.
go back to reference Hansson-Lundblad C, Holm K, Agardh CD, Agardh E (2002) A small number of older type 2 diabetic patients end up visually impaired despite regular photographic screening and laser treatment for diabetic retinopathy. Acta Ophthalmol Scand 80:310–315PubMedCrossRef Hansson-Lundblad C, Holm K, Agardh CD, Agardh E (2002) A small number of older type 2 diabetic patients end up visually impaired despite regular photographic screening and laser treatment for diabetic retinopathy. Acta Ophthalmol Scand 80:310–315PubMedCrossRef
22.
go back to reference (1994) Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94, series 1: programs and collection procedures. Vital Health Stat 32: 1–407 (1994) Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94, series 1: programs and collection procedures. Vital Health Stat 32: 1–407
23.
go back to reference Diabetic Retinopathy Study Research Group (1981) Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings. DRS report no. 8. Ophthalmology 88:583–600 Diabetic Retinopathy Study Research Group (1981) Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings. DRS report no. 8. Ophthalmology 88:583–600
24.
go back to reference Early Treatment Diabetic Retinopathy Study Research Group (1991) Early photocoagulation for diabetic retinopathy. ETDRS report no. 9. Ophthalmology 98:766–785 Early Treatment Diabetic Retinopathy Study Research Group (1991) Early photocoagulation for diabetic retinopathy. ETDRS report no. 9. Ophthalmology 98:766–785
25.
go back to reference Stratton IM, Aldington SJ, Taylor DJ, Adler AI, Scanlon PH (2013) A simple risk stratification for time to development of sight-threatening diabetic retinopathy. Diabetes Care 36:580–585PubMedCrossRef Stratton IM, Aldington SJ, Taylor DJ, Adler AI, Scanlon PH (2013) A simple risk stratification for time to development of sight-threatening diabetic retinopathy. Diabetes Care 36:580–585PubMedCrossRef
26.
go back to reference Hutchinson A, McIntosh A, Peters J et al (2000) Effectiveness of screening and monitoring tests for diabetic retinopathy. A systematic review. Diabet Med 17:495–506PubMedCrossRef Hutchinson A, McIntosh A, Peters J et al (2000) Effectiveness of screening and monitoring tests for diabetic retinopathy. A systematic review. Diabet Med 17:495–506PubMedCrossRef
Metadata
Title
Clinical characteristics influence screening intervals for diabetic retinopathy
Authors
Massimo Porta
Mauro Maurino
Sara Severini
Elena Lamarmora
Marina Trento
Elena Sitia
Eleonora Coppo
Alessandro Raviolo
Stefania Carbonari
Marcello Montanaro
Lorenza Palanza
Paola Dalmasso
Franco Cavallo
Publication date
01-10-2013
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 10/2013
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-013-2989-7

Other articles of this Issue 10/2013

Diabetologia 10/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.